News and Events

Photomicrograph of a diffuse large B-cell lymphoma

New insights into the origins of an aggressive form of lymphoma

A new study sheds light on the origin of an aggressive subtype of diffuse large B cell lymphoma (DLBCL). The findings could help researchers develop more targeted therapies for this form of blood cancer.

Bacteria inside lung tumors concentrate within cancer cells

Researchers discovered that tumor-promoting signals are elevated in lung tumor cells with high concentrations of bacteria. These findings support the idea that reducing bacteria in the lungs might be beneficial for patients with lung cancer.

Cytotoxic T cells (red) are shown attacking a squamous cancer cell (white).

Immune receptors recognizing mutations in p53 could guide immunotherapies for solid tumors

CCR scientists have assembled a library of immune receptors that direct T cells to target cells with mutations in p53, the most commonly mutated gene in human cancers.

CCR postdoctoral researcher awarded Fulbright to study HPV and cervical cancer in Africa

Tsion Minas, Ph.D., is a recent recipient of a Fulbright U.S. Scholar Award. She joined the Laboratory of Human Carcinogenesis in 2016 to work with Senior Investigator Stefan Ambs, Ph.D., M.P.H., and study the molecular nature of cancers in African populations. In this Q&A, she shares her passion for closing disparity gaps in health research and how she plans to build upon her Fulbright work in the future.

Microscopic view of a tissue sample of ductal cell carcinoma from human breast cancer. Image credit: Allan Weissman, M.D., Senior Investigator in the Cancer Innovation Laboratory at CCR, and Kevin Gardner, M.D., Ph.D., Professor of Pathology and Cell Biology at Columbia University.

A protein predicts poor breast cancer survival for women of African descent

CCR and Columbia University researchers have discovered that large amounts of the gp78 protein in breast cancer tumors predict worse outcomes for patients of African ancestry. Their findings provide some new understanding of a significant health disparity in breast cancer.

pattern of DNA methylation in a meningioma tumor

New way to classify meningioma brain tumors suggests potential treatments

Two studies have found a new way to classify meningioma, a type of tumor that forms in the outer covering of the brain. Kenneth Aldape, M.D., Chief and Senior Investigator of the Laboratory of Pathology, speaks about how the new grouping system may help predict whether a patient’s tumor will grow back after treatment and may reveal new treatment possibilities.

2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology

Registration and abstract submission is now open for the 2022 Cancer Immunology and Immunotherapy Conference: Discovery to Mainstream Oncology.

This two-day national conference provides a venue for scientists world-wide to exchange the latest information on the immunotherapy of cancer. We are looking forward to an exciting forum for discussion and debate on the current understanding of cancer and immunology and immunotherapy.

Sessions include:

CAR T-Cell Based Immunotherapies
Cell Therapy for Solid Epithelial Cancers
Principles of Checkpoint Modulators
Clinical Applications of Checkpoint Modulators
Microbiome and Immunotherapy
Factors Influencing the Success of Immunotherapy
Innovative Approaches to Immunotherapy

Clinical trial researches immunotherapy for recurrent thymoma and thymic carcinoma

A clinical trial led by Arun Rajan, M.D., Senior Clinician in the Thoracic and GI Malignancies Branch, is researching treatments, including immunotherapy, for recurrent thymoma and thymic carcinoma.

ALIGNED for Pride

June is Pride Month, a celebration of LGBTQIA+ folks that dates back to the 1969 Stonewall Uprising. Pride is a time to celebrate our family, friends and colleagues in the LGBTQIA+ community and the strides that have been made towards equity and justice for all. For this edition of Aligned, I asked a few friends and colleagues to tell me what Pride means to them.

Sung-Yun Pai selected for Hedwig van Ameringen Executive Leadership in Academic Medicine® (ELAM) Program

Sung-Yun Pai, M.D., Chief of the Immune Deficiency Cellular Therapy Program, was selected for the Hedwig van Ameringen Executive Leadership in Academic Medicine® (ELAM) Program for Women at Drexel University College of Medicine. The ELAM® program is dedicated to developing leadership and management skills in healthcare and is designed for senior-level women leaders interested in advancing hospitals and healthcare systems.

Breadcrumb